Cadonilimab, a bispecific antibody targeting two immune-related pathways, showed a survival advantage over PD-1-based regimens in gastric cancer and gastroesophageal junction cancer, according to the reported analysis. The work positions the therapy as a potential next option for patients where checkpoint inhibitor strategies have limitations. With gastric cancer remaining difficult to treat due to late diagnosis and frequent spread, the dataset emphasizes differentiating mechanisms—rather than only durability metrics—when comparing against PD-1 drugs. Developers and clinicians are likely to scrutinize subgroup definitions and endpoints as the field evaluates how bispecifics may complement or replace checkpoint inhibition.